Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH

Endocrine Journal

Volumn 53, Issue 6, 2006, Pages 723-728

  Sugino, Kiminori ^a   Ito, Koichi ^a   Takami, Hiroshi ^b  

^a ITO HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Differentiated thyroid cancer; Recombinant human TSH; Thyroglobulin; Whole body 131I scan

Indexed keywords

IODINE 131; LIOTHYRONINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN;

ASTHENIA; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CLINICAL TRIAL; CONGENITAL HYPOTHYROIDISM; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC IMAGING; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; EUROPE; FLUSHING; FOLLOW UP; HEADACHE; HEMIPARESIS; HEMIPLEGIA; HORMONAL THERAPY; HUMAN; HYPOTHYROIDISM; NAUSEA; NODULAR GOITER; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; UNITED STATES; URTICARIA; VISUAL IMPAIRMENT; VOMITING; WHOLE BODY SCINTISCANNING;

CARCINOMA; HUMANS; IODINE RADIOISOTOPES; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN;

EID: 33846008392     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.KR-88     Document Type: Review

References (28)

1. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428.
2. British Thyroid Association (2002) Guidelines for the management of differentiated thyroid cancer in adults. available at www.british-thyroid- association.org/guidelines.htm
3. American Thyroid Association (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. available at www.thyroid.org/
4. th meeting of the Japanese society of thyroid surgery. Endocr J 52: 479-491.
5. Guidon PT Jr, Whitfield GK, Porti D, Kourides IA (1988) The human thyrotropin beta-subunit gene differs in 5′ structure from murine TSH-beta genes. DNA 7: 691-699.
6. Wondisford FE, Radovick S, Moates JM, Usala SJ, Weintraub BD (1988) Isolation and characterization of the human thyrotropin beta-subunit gene. Differences in gene structure and promoter function from murine species. J Biol Chem 263: 12538-12542.
7. Huber GK, Fong P, Concepcion ES, Davies TF (1991) Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 72: 1328-1331.
8. Thotakura NR, Desai RK, Bates LG, Cole ES, Pratt BM, Weintraub BM (1991) Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 128: 341-348.
9. Ramirez L, Braverman LE, White B, Emerson CH (1997) Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab 82: 2836-2839.
10. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH (2001) Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 86: 1660-1664.
11. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, DeGroot LJ, Curran P, McEllin K, Reynolds J, Robbins J, Weintraub BD (1994) Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 78: 188-196.
12. Landenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD (1997) Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337: 888-896.
13. Haugen BR, Pacini F, Reiners C, Schlumberger M, Landenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davis TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon III HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84: 3877-3885.
14. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD (2001) Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86: 619-625.
15. Pacini F, Lippi F (1999) Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement. J Endocrinol Invest 22 (Suppl): 25-29.
16. Reiners C, Luster M, Lassmann M (1999) Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131. J Endocrinol Invest 22 (Suppl): 17-24.
17. Mariani G, Ferdeghini M, Augeri C, Villa G, Taddei GZ, Scopinaro G, Boni G, Bodei L, Rabitti C, Molinari E, Bianchi R (2000) Clinical experience with recombinant human thyrotropin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharm 15: 211-217.
18. David A, Blotta A, Bondanelli M, Rossi E, Braverman LE, Busutti L, degli Uberti EC (2001) Serum thyroglobulin concentrations and 131I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 42: 1470-1475.
19. Giovanni V, Arianna LG, Antonio C, Francesco F, Michele K, Giovanni S, Marco S, Giovanni L (2002) The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol 56: 247-252.
20. Cailleux AF, Baudin E, Travegli JP, Ricard M, Schlumberger M (2000) Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85: 175-178.
21. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A (2002) Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87: 1499-1501.
22. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A (2001) Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 86: 5686-5690.
23. Mazzaferri EL, Kloos RT (2002) Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87: 1490-1498.
24. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT (2002) Clinical comparison of whole-body radio-iodine scan and thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 12: 37-43.
25. Wartofsky L, and the rhTSH-Stimulated Thyroglobulin Study Group (2002) Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12: 583-590.
26. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Landenson PW, Pinchera A (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88: 1433-1441.
27. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM (2002) Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 87: 3242-3247.
28. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A (2003) Recombinant human thyrotropin- stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88: 3668-3673.